Can-Fite Biopharma Ltd ADR: Navigating a Turbulent Year, Up -73.98% from 52-Week Low

The stock of Can-Fite Biopharma Ltd ADR (CANF) is currently priced at $2.33. In the last session, the stock climbed significantly, topping out at $2.01 after opening at $1.98. The day’s lowest price was $1.96 before the stock closed at $2.01.

The market performance of Can-Fite Biopharma Ltd ADR’s stock has been turbulent in recent times. Over the last year, the company’s stock reached its highest point at $8.95 on 11/25/22, while the lowest value for the same duration was $1.52 on 04/12/23.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


52-week price history of CANF Stock

A stock’s 52-week high and low prices can reveal much about its current status and future trajectory. Can-Fite Biopharma Ltd ADR’s current trading price is -73.98% away from its 52-week high, while its distance from the 52-week low is 53.20%. The stock’s price range during this period has spanned from $1.52 to $8.95. In the Healthcare sector, the Can-Fite Biopharma Ltd ADR’s shares surpassed a trading volume of approximately 2.6 million for the day, which was noticeably higher compared to the average daily volume of 9.7900.0 over the past three months.

Market Capitalization and Financial Performance: An In-Depth Look

Can-Fite Biopharma Ltd ADR (CANF) has experienced a quarterly decline of -10.15% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 9.50M.

A Closer Look at Analysts’ Ratings for Can-Fite Biopharma Ltd ADR

As of right now, 2 analysts are rating Can-Fite Biopharma Ltd ADR as a BUY, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analyst is recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.

Making Sense of Trading Volume and Moving Average Data

Based on Barchart.com data, the company’s moving average over the 100-day period was 2.57, with a change in price of -0.72. Similarly, Can-Fite Biopharma Ltd ADR recorded 34,058 in trading volume during the last 100 days, posting a change of -23.45%.

Examining CANF’s Debt-to-Equity Ratio: What You Need to Know

The debt-to-equity (D/E) ratio is a crucial measure that sheds light on a company’s financial health and market standing. It is determined by dividing a company’s overall liabilities by its shareholders’ equity, showing the extent of a company’s debt usage in financing its assets compared to the shareholders’ equity. At the time of writing, the total D/E ratio for CANF stands at 0.01. Similarly, the long-term debt-to-equity ratio is also 0.00.

CANF Stock Stochastic Average

Today’s raw stochastic average for Can-Fite Biopharma Ltd ADR over the last 50 days is 50.47%.This indicates a decrease from the raw stochastic average of the past 20 days, which was 90.76%. Moreover, the company’s Stochastic %K and %D values for the last 20 days were 62.27% and 48.39%, respectively.

CANF Stock Price Performance Analysis

The stock price performance this year has been a mixed bag, which means people have different opinions about whether it’s been good or bad. Some may see it as optimistic, while others may view it as pessimistic. The metric has seen a significant loss of -62.01% since the start of this calendar year. Looking back over the last six months, we can see a stronger performance of -1.74%. Over the past 30 days, the price of CANF has fallen by 21.29%. And in the last five days, it has surged by 21.29%.

Leave a Reply

Your email address will not be published. Required fields are marked *

On Key

Related Posts